Abstract
Purpose
The purpose of this study was to evaluate the pharmacokinetics and toxicity of a chitosan (CS) and polylactic acid (PLA) based methotrexate (MTX) intravitreal micro-implant in an animal model using rabbit eyes.
Methods
CS- and PLA-based micro-implants containing 400 μg of MTX were fabricated using lyophilization and dip-coating techniques. The micro-implants were surgically implanted in the vitreous of eight New Zealand rabbits employing minimally invasive technique. The PLA-coated CS-MTX micro-implant was inserted in the right eye and the placebo micro-implant in the left eye of each rabbit. Two rabbits were euthanized at each pre-determined time point post-implantation (days 5, 12, 19, and 33) for pharmacokinetics and histopathology evaluation.
Results
A therapeutic concentration of MTX (0.1–1.0 μM) in the vitreous was detected in the rabbit eyes studied for 33 days. The MTX release from the coated micro-implants followed a first order kinetics (R 2 ~ 0.88), implying that MTX release depends on the concentration of MTX in the micro-implant. Histopathological analysis of the enucleated eyes failed to show any signs of infection or tissue toxicity in any of the specimens.
Conclusion
The PLA-coated CS-MTX micro-implants were able to deliver therapeutic release of MTX for a period of more than 1 month without detectable toxicity in a rabbit model. The micro-implants can be further investigated as a prospective alternative to current treatment protocols of repeated intravitreal MTX injections in intraocular disorders such as primary intraocular lymphoma, and selected cases of non-microbial intraocular inflammation.
Similar content being viewed by others
References
Khalatbari D, McCallum RM, GJ J (2003) Methotrexate. A patient education monograph prepared for the American Uveitis Society. American Uveitis Society. http://www.uveitissociety.org/pages/diseases/methotrexate.html. Accessed 25 March 2015
Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H (2006) Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 142(5):883–885
Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay JY, Ferreri AJ, Omuro AM, Thiel E, Abrey LE (2007) Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 18(11):1851–1855
Nakauchi Y, Takase H, Sugita S, Mochizuki M, Shibata S, Ishiwata Y, Shibuya Y, Yasuhara M, Miura O, Arai A (2010) Concurrent administration of intravenous systemic and intravitreal methotrexate for intraocular lymphoma with central nervous system involvement. Int J Hematol 92(1):179–185
Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J (2008) Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 92(3):383–388
Sampat KM, Garg SJ (2010) Complications of intravitreal injections. Curr Opin Ophthalmol 21(3):178–183
Ozkan EB, Ozcan AA, Sekeroglu HT, Kuyucu Y, Ozgun H, Polat S (2013) Intravitreal injection of methotrexate in an experimental rabbit model: determination of ultrastructural changes. Indian J Ophthalmol 61(7):329–333
Gorovoy I, Prechanond T, Abia M, Afshar AR, Stewart JM (2013) Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid. Cornea 32(8):1171–1173
Kuroiwa N, Abematsu N, Matsuo Y, Nakao K, Sakamoto T (2011) A case of intraocular lymphoma having retinal adverse events associated with intravitreal methotrexate. Nihon Ganka Gakkai Zasshi 115(7):611–616
Palakurthi NK, Krishnamoorthy M, Augsburger JJ, Correa ZM, Banerjee RK (2010) Investigation of kinetics of methotrexate for therapeutic treatment of intraocular lymphoma. Curr Eye Res 35(12):1105–1115
Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chan CC, Nussenblatt RB, Robinson MR (2001) Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 119(10):1518–1524
Manna S, Augsburger JJ, Correa ZM, Landero JA, Banerjee RK (2014) Development of chitosan and polylactic acid based methotrexate intravitreal micro-implants to treat primary intraocular lymphoma: an in vitro study. J Biomech Eng 136(2):021018
USP method for HPLC analysis of methotrexate. The United States Pharmacopeial Convention 2010. http://www.chem.agilent.com/Library/applications/(PH23)5988-6394EN.pdf. Accessed 25 March 2015
de Smet MD, Vancs VS, Kohler D, Solomon D, Chan CC (1999) Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 83(4):448–451
Lee S, Hughes P, Ross A, Robinson M (2010) Biodegradable implants for sustained drug release in the eye. Pharm Res 27(10):2043–2053
Palakurthi NK, Correa ZM, Augsburger JJ, Banerjee RK (2011) Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study. J Ocul Pharmacol Ther 27(2):151–156
Stainer GA, Peyman GA, Berkowitz R, Tessler HH (1976) Intraocular lysozyme in experimental uveitis in rabbits: aqueous and vitreous assay. Invest Ophthalmol Vis Sci 15(4):312–315
Pe’er J, Hochberg FH, Foster CS (2009) Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm 17(5):299–306
Chan CC, Wallace DJ (2004) Intraocular lymphoma: update on diagnosis and management. Cancer Control : J Moffitt Cancer Cent 11(5):285–295
de la Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ (2010) Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62(1):100–117
Kunou N, Ogura Y, Hashizoe M, Honda Y, Hyon S-H, Ikada Y (1995) Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J Control Release 37(1-2):143–150
Yasukawa T, Kimura H, Tabata Y, Ogura Y (2001) Biodegradable scleral plugs for vitreoretinal drug delivery. Adv Drug Deliv Rev 52(1):25–36
Fialho SL, Rêgo MB, Siqueira RC, Jorge R, Haddad A, Rodrigues AL, Maia-Filho A, Silva-Cunha A (2006) Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit ryes. Curr Eye Res 31(6):525–534
Acknowledgments
This study was supported in part by the combined research assistantship program of the University of Cincinnati’s College of Engineering and Applied Science and an Unrestricted Grant from Research to Prevent Blindness, Inc, New York, NY to the Department of Ophthalmology, University of Cincinnati (James J. Augsburger, M.D., Chairman). The authors would like to acknowledge the support of Anukana Bhattacharjee, Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati in sterilizing the micro-implants. The authors would also like to acknowledge the support of Laboratory Animal Medical Services, University of Cincinnati is assisting with the rabbit experiments. Lastly, the authors would like to acknowledge Dr. Julio A. Landero of the Department of Chemistry, University of Cincinnati for facilitating the micro-implant fabrication process and the HPLC study.
Author disclosure statement
No competing financial interests exist.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manna, S., Banerjee, R.K., Augsburger, J.J. et al. Biodegradable chitosan and polylactic acid-based intraocular micro-implant for sustained release of methotrexate into vitreous: analysis of pharmacokinetics and toxicity in rabbit eyes. Graefes Arch Clin Exp Ophthalmol 253, 1297–1305 (2015). https://doi.org/10.1007/s00417-015-3007-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-015-3007-1